Clinical Trial Update: An Open-Label, Dose-Escalation Study of AZD2461 [Phase 1]

View source ↗

Summary

Open-label, dose-escalation Phase 1 trial of AZD2461 in patients with refractory solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• AZD2461 (AZD2461)

Snippet

Sponsor: AstraZeneca | Conditions: Refractory Solid Tumors, Cancer Tumor | Phase 1 | Status: COMPLETED